Výsledky vyhledávání - "Véronique Trochon-Joseph"

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

Autor: Diana Llopiz, Graham Dixon, Bruno Sangro, Bérangère Vasseur, Josune Egea, Perrine Pivette, Pablo Sarobe, Tamara Iglesias, Lorea Villanueva, Marta Ruiz, Véronique Trochon-Joseph, Juan José Lasarte, Leyre Silva

Publikováno v: Cancer Immunology, Immunotherapy. 68:379-393

Immune checkpoint inhibitors are currently tested in different combinations in patients with advanced hepatocellular carcinoma (HCC). Nivolumab, an anti-PD-1 agent, has gained approval in the second-line setting in the USA. Epigenetic drugs have immu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a977f8de576b97989a62c967de20844
https://doi.org/10.1007/s00262-018-2283-0

Zobrazit plný text záznamu

Biodistribution of polycyanoacrylate nanoparticles encapsulating doxorubicin by Matrix-Assisted Laser Desorption Ionization (MALDI) Mass Spectrometry Imaging (MSI)

Autor: Aurore Tomezyk, Mathieu Gaudin, Bérangère Vasseur, Raphael Legouffe, David Bonnel, Véronique Trochon-Joseph, Norbert Bromet, Jonathan Stauber, Christelle Zandanel

Publikováno v: Journal of Drug Delivery Science and Technology. 47:55-61

Nanoparticles are widely used as carrier for the delivery of Active Principle Ingredients (API). From safety point of view, the fate of nanoparticles and API after administration becomes a key question. Today qualitative and quantitative biodistribut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23d3b8a7f51bf5eab8406e877fb53143
https://doi.org/10.1016/j.jddst.2018.06.023

Zobrazit plný text záznamu

Abstract 527: A new generation of PARP interfering drug candidates for cancer treatment

Autor: Wael Jdey, Vincent Hayes, Christelle Zandanel, Véronique Trochon-Joseph, Chloé Doizelet, Françoise Bono, Richard Tripelon, Marie-Christine Lienafa

Publikováno v: Cancer Research. 81:527-527

Purpose: Therapeutic strategies targeting DNA repair defects have been widely explored, but often restricted to a specific population of patients and tackled with resistance issues. We pioneered a new approach of anti-cancer treatment to tackle emerg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b034c5b672c86c784e0491b73c6ee98c
https://doi.org/10.1158/1538-7445.am2021-527

Zobrazit plný text záznamu

Abstract 4078: Acquired resistance to PARP inhibitors evolves from drug-tolerant cells vulnerable to AsiDNA

Autor: Wael Jdey, Françoise Bono, Véronique Trochon-Joseph, Marie-Christine Lienafa, Aurelie Dubois, Loane Ratel

Publikováno v: Cancer Research. 80:4078-4078

Purpose: PARP inhibitors (PARPi) resistance remains a major clinical hurdle as virtually all patients treated with PARPi will eventually relapse. We already demonstrated that co treatment with AsiDNA abrogates and reverses PARPi-acquired resistance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aded0f43037ae5af37269401b608c3e
https://doi.org/10.1158/1538-7445.am2020-4078

Zobrazit plný text záznamu

Abstract 2818: AsiDNA and HDAC inhibitors: A cross-potentiation team working to kill tumor cells

Autor: Marie Dutreix, Jean-Louis Labernardière, Richard Tripelon, Françoise Bono Colombie, Laura Bellassen, Hélène Toussaint, Véronique Trochon-Joseph, Perrine Pivette, Coraline Cassegrain, Wael Jdey, Vincent Hayes

Publikováno v: Cancer Research. 78:2818-2818

Purpose: while being registered and used in restricted subset of T-cell lymphoma, HDAC inhibitors (HDACi) have shown limited antitumor effect as single agents. Recent studies have shown an effect of HDACi on DNA damage accumulation, rationalizing the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ea767e02f12a5f78159d4dfcd1c172a
https://doi.org/10.1158/1538-7445.am2018-2818

Zobrazit plný text záznamu

Abstract 1059: Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model

Autor: Perrine Pivette, Pablo Sarobe, Caroline Lemarchand, Véronique Trochon-Joseph, Bruno Sangro, Bérangère Vasseur, Marta Ruiz, Graham Dixon, Diana Llopiz

Publikováno v: Cancer Research. 77:1059-1059

Introduction Belinostat is an HDAC inhibitor currently marketed in the US for the treatment of PTCL. A new oral formulation is under development (positive PoC in preclinical PK study) and provides an increase potential to develop new indications of b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3705e948e0530a29490c870dc63b018a
https://doi.org/10.1158/1538-7445.am2017-1059

Zobrazit plný text záznamu

Abstract 3076: A novel nanoparticle formulation of doxorubicin is clearly differentiated from free doxorubicin in overcoming resistance mechanisms in chemo-resistant tumors

Autor: Jean-Louis Labernardière, Vincent Hayes, Caroline Lemarchand, Véronique Trochon-Joseph, Séverine Rochas, Françoise Bono, Yamina Rayah, Graham Dixon, Christelle Zandanel

Publikováno v: Cancer Research. 77:3076-3076

Background and Aims. Chemo-resistance in hepatocellular carcinoma (HCC) tumor cells can be mediated by several mechanisms including P-gp efflux pumps and drug sequestration by the autophagy process. This study investigates the potential of doxorubici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b10ec38501e85271730a2ed596a279f0
https://doi.org/10.1158/1538-7445.am2017-3076

Zobrazit plný text záznamu

Abstract 2143: Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines

Autor: Graham Dixon, Véronique Trochon-Joseph, Caroline Lemarchand, Yamina Rayah, Jean-Louis Labernardière, Vincent Hayes

Publikováno v: Cancer Research. 76:2143-2143

Background and Aims Efficacy of doxorubicin encapsulated into a biodegradable network (NP) is currently studied in phase III compared to Best Standard of Care in patients with advanced HCC (Relive study). Preclinical studies demonstrated that NP allo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::957db60d403a7f6752d6e6095d7b71bb
https://doi.org/10.1158/1538-7445.am2016-2143

Zobrazit plný text záznamu

Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions

Autor: Grete K. Jacobsen, Céline Bouquet, Véronique Trochon-Joseph, Katrin Wallbrecht, Louise S. Villadsen, John Robert Zibert, Cadossi Ruggero, Michael P. Schön, Lluis M. Mir, Lone Skov, Margarete Schön

Publikováno v: The Journal of clinical investigation. 121(1)

Dysregulated angiogenesis is a hallmark of chronic inflammatory diseases, including psoriasis, a common skin disorder that affects approximately 2% of the population. Studying both human psoriasis in 2 complementary xenotransplantation models and pso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce0a0ea10f63c88a3c9f027405e3039
https://pubmed.ncbi.nlm.nih.gov/21135506

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání